Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1845-1849

  Arah, Ifeyinwa N ^a   Song, Kaimei ^a   Seth, Prem ^a   Cowan, Kenneth H ^a   Sinha, Birandra K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; Apoptosis prostate tumor; Camptothecin; p53

Indexed keywords

CAMPTOTHECIN; CISPLATIN; DNA FRAGMENT; DNA TOPOISOMERASE; PROTEIN P21; PROTEIN P53;

ADENOVIRUS; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE MUTATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN SYNTHESIS;

ADENOVIRIDAE; APOPTOSIS; CAMPTOTHECIN; CELL DEATH; CISPLATIN; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENETIC VECTORS; HUMANS; KINETICS; MALE; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031830411     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Merino A, Madden KR, Lane WS, Champoux JJ and Reinberg D: DNA topoisomerase I is involved in both repression and activation of transcription. Nature 365: 227-232, 1993.
2. Wall M, Wani MC, Cook CE, Palmer KH, McPhail AT and Sim GA: Plants antitumor agents 1. The isolation and structure of camptothecin, a novel alkaloid leukemia and antitumor inhibitor from camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966.
3. Sinha BK: Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 49: 11-19, 1995.
4. Giovanella BC, Hinz HR, Kozielsi AJ, Stehlin Jr JS, Silber S and Potmesil M: Complete growth inhibition of human tumor xenografts in nude mice by treatment with 20-[S]-camptothecin. Cancer Res 51: 3052-3055, 1991.
5. Masuda N, Fakuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudda S, Negoro S, Nishioka M, Nakagaw K and Takadda M: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10: 1225-1230, 1992.
6. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastier AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kauffman SH and Donehower RC: Phase I and pharmacological studies of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10: 647-656, 1992.
7. Wang Z and Sinha BK: Interleukin-1 a-induced modulation of topoisomerase I activity and DNA damage: Implications in the mechanisms of synergy with camptothecins in vitro and in vivo. Mol Pharm 49: 269-275, 1996.
8. Wang Z, Benchekuroun MN and Sinha BK: Potentiation of antitumor activities of carboplatin and camptothecin by interleukin-a against human ovarian carcinoma in vivo. Anticancer Res 14: 1723-1726, 1994.
9. Nigro JM, Baker JS, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FC, Weston A, Modali R, Harris CC and Vogelstein B: Mutation in p53 gene occur in diverse human tumor types. Nature 342: 705-708, 1989.
10. Takahashi N, Nau MM, Chiba I, Brirer MJ, Rosenberg RK, Vinacour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
11. Dulic' V, Kaufmann WK, Wilson SJ, Tlstry TD, Lees E, Harper JW, Elledge SJ and Reed SI: p53-dependent inhibition of cyclin-dependent kinase activities in human tibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023, 1994.
12. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852, 1993.
13. Michalovitz D, Halevy O and Oren M: Conditional inhibition of transformation and cell proliferation by a temperature-sensitive mutant of p53. Cell 62: 671-680, 1990.
14. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Nature 362: 847-849, 1993.
15. Gobert C, Bracco L, Rossi F, Oliver M, Tazi J, Lavelle F, Larsen AK and Riou JF: Modulation of DNA topoisomerase I activity by p53. Biochemistry 35: 5778-5786, 1996.
16. Katyose D, Gudas J, Nguyen H, Srivastava S, Cowan KH and Seth P: Cytotoxic effects of adenovirus mediated wild type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1: 889-897, 1995.
17. Srivastava S, Katyose D,Tong YA, Craigs CR, McLeod DG, Moul JD, Cowan KH and Seth P: Recombinant adenovirus vector expressing wild type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology 46: 843-848, 1995.
18. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR: Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48: 589-601, 1988.
19. Eliot HE, Borner MM and Sinha BK: Differential oncogene expression and susceptibility to apoptosis in human leukemia HL60 cell lines: implications in the mechanisms of etoposide resistance. Anticancer Res 15: 729-734, 1995.
20. Sinha BK, Yamazaki H, Eliot HM, Schneider E, Borner MM and O'Conner PM: Relationship between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cell lines. Biochim Biphys Acta 7270: 12-18, 1995.
21. Xlong Y, Hannon GJ, Zhang H, Casso D, Kobayaski R and Beach D: p21 is a universal inhibitor of cyclin kinase. Nature 366: 701-704, 1993.
22. Harper JW, Adani GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk interacting Cip1 is a potential inhibitor of G1 cyclin-dependent kineses. Cell 75: 805-816, 1993.
23. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging applications in tissue kinetics. Br J Cancer 26: 239-527, 1972.
24. Lowe SW, Ruley HE, Jachs T and Housman DE: Abrogation of oncogene-associated apoptosis allows transformation of p-53 deficient mouse. Cell 74: 957-967, 1993.